Anlon Healthcare Limited reported a consolidated total income of ₹87.62 crore for the first quarter of FY27 (Q1FY27), marking a substantial increase from ₹33.31 crore in Q1FY26. The surge in top-line figures was primarily driven by the consolidation of its recent acquisition, Remember India Health links, alongside organic growth in core businesses. Profit after tax (PAT) rose to ₹8.28 crore from ₹3.55 crore in the prior year period, while EBITDA stood at ₹15.65 crore compared to ₹6.26 crore previously. These results were disclosed in an earnings conference call held on August 06, 2026, and filed with stock exchanges pursuant to Regulation 30 of SEBI-LODR.

Despite the revenue growth, EBITDA margins moderated to approximately 17% in the quarter. Managing Director Punit Rasadia attributed this compression to two main factors: a sharp increase in raw material prices due to global geopolitical situations, which temporarily impacted cost structures, and the consolidation of operating expenses from Remember India Health links, which is currently in an investment and turnaround phase. The company has initiated price revisions to offset higher input costs and expects margins to gradually recover.

Strategic Acquisitions and Capacity Expansion

Q1FY27 marked a transformational period for Anlon as it completed the acquisition of a 63.98% stake in Remember India Health links on May 08, 2026. This move signals Anlon’s entry into finished dosage formulations, including tablets, capsules, and ointments, providing access to over 30 formulation dossiers. Previously focused on pharmaceutical intermediates and APIs, the company is transitioning into a more integrated pharmaceutical platform spanning B2B APIs, domestic retail, and hospital markets.

Alongside this, Anlon continues to advance its backward integration strategy through subsidiaries Apiqo Organics and Bizotic Lifesciences. Apiqo strengthens capabilities for critical pharmaceutical intermediates and industrial fine chemicals, while Bizotic provides a ready-to-operate manufacturing facility. Together, these entities have expanded Anlon’s installed manufacturing capacity to approximately 1,400–1,600 metric tons per annum. Current capacity utilization stands at 65–70%, with management targeting optimal utilization to drive revenue toward the ₹350–400 crore range for FY27.

Financial Performance Breakdown

The following table outlines the key financial metrics for Q1FY27 compared to the corresponding period in FY26:

Revenue contributions from subsidiaries in Q1FY27 were approximately ₹45 crore from Apiqo Organics, ₹12 crore from Bizotic Lifesciences, and ₹32 crore from standalone Anlon operations. Remember India Health links did not contribute significantly to revenue as it remains in the operational upgrade and validation stage.

What the Numbers Show

The divergence between strong revenue growth and compressed margins highlights the transitional nature of Anlon’s current business model. While the acquisition-driven scale expansion is evident in the near-tripling of total income, the integration costs and external pressure from raw material prices—specifically petroleum-based solvents which have seen price increases of two to three times pre-war levels—are weighing on profitability. Management indicated that methanol prices, for instance, rose from ₹22 to ₹58–60 per unit. However, the company has successfully passed on some cost increases to customers, expecting margin normalization to the 25–30% range by Q3FY27 as input costs stabilize and integration benefits flow through. The company also projects a long-term revenue CAGR of approximately 30% over the next three years, supported by its expanded manufacturing platform and diversified product portfolio.

Anlon Healthcare has moved to expand its footprint in the pharmaceutical intermediates and active pharmaceutical ingredients (API) space by executing share swap agreements for two target entities. On August 8, 2026, the company signed deals to acquire up to 32.52% stake in Apiqo Organics Private Limited (AOPL) and up to 43.33% stake in Bizotic Lifescience Private Limited (BLPL). The transactions, valued at approximately ₹116.52 crore and ₹36.78 crore respectively, will be settled through the preferential allotment of Anlon Healthcare’s equity shares, preserving its cash reserves while securing strategic supply chain synergies.

The acquisitions qualify as related party transactions under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as promoters and directors are common across the entities. Both deals are structured on an arm’s length basis and require listing approvals from stock exchanges for the newly issued shares. The Board of Directors had previously intimated these proposals in a meeting held on July 30, 2026.

Deal Structure and Consideration

The consideration for both acquisitions will be discharged via share swaps at predetermined exchange ratios, with no cash outflow expected from Anlon Healthcare. For Apiqo Organics, the company will issue up to 45,16,200 equity shares at a price of ₹258 each. For Bizotic Lifescience, it will issue up to 22,99,000 equity shares at ₹160 each.

In total, Anlon Healthcare proposes to issue up to 8,58,83,617 equity shares with a face value of ₹2 each. The share exchange ratio is set at [1:14.45] for AOPL shareholders and [1:8.96] for BLPL shareholders. Any fractional entitlements will be rounded off to the nearest whole equity share.

Target Company Profiles

Apiqo Organics Private Limited, incorporated on December 1, 2025, following conversion from a partnership firm, manufactures pharmaceutical intermediates, industrial, fine, and inorganic chemicals. Its turnover surged from ₹977.78 lakh in FY24-25 to ₹7,254.11 lakh in FY25-26, indicating rapid scaling. Bizotic Lifescience Private Limited, incorporated in April 2015, specializes in manufacturing and exporting pharmaceutical drugs, APIs, and providing contract research and manufacturing services. Its turnover grew from ₹380.39 lakh in FY23-24 to ₹3,126.64 lakh in FY25-26.

Timeline and Regulatory Approvals

Both acquisitions are subject to customary closing conditions and shareholder acceptance of the share swap proposals. The company expects to complete the acquisitions within 90 days from the signing date or as mutually agreed. Listing and trading approvals from stock exchanges are required for the preferential issue of shares. The disclosures were made pursuant to Regulation 30 read with Part-A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

What the Numbers Show

The aggressive expansion strategy highlights Anlon Healthcare’s focus on vertical integration within the pharma supply chain. By acquiring controlling or significant minority stakes in API and intermediate manufacturers, the company aims to secure critical material supplies and enhance operational efficiency. The use of share swaps instead of cash preserves liquidity, though it dilutes existing shareholders; promoters Punitkumar Rameshbhai Rasadia and Meet Atulkumar Vachhani will see their holdings increase from 18,59,20,000 and 9,40,80,000 shares to approximately 20,43,39,402 and 10,34,31,099 shares respectively, assuming full acceptance by all target company shareholders.